Introduction
Germ-cell tumors (GCTs) have been highly curable cancers since the introduction of cisplatin-based chemotherapy. The prognosis of patients with GCTs has improved dramatically in recent years, and nowadays approximately 80% of patients with metastatic disease can be cured, including those with far-advanced disease [1] . However, a small proportion of patients still die of the disease [2] . Some features that allow identification of subsets of patients at high risk of poor outcome have been described [3, 4] , and the International Germ-Cell Consensus Classification (IGCCC) recently defined a group of patients with an extremely poor prognosis [5] .
Whereas in patients with good prognosis the decrease of toxic effects is a major goal [6] , in the group of patients with poor-prognosis features, the main objective is to increase the cure rate. Therefore, attempts are being made to improve the survival of that group of patients by using new approaches, such as intensification of the chemotherapy, the introduction of new agents into firstline therapy, and the use of alternating or sequential drug combinations [7] .
We performed a multicentre study to evaluate the efficacy and toxicity of the intensive alternating chemotherapy regimen BOMP/EPI in patients with non-seminomatous GCTs with poor-prognosis disease according to the IGCCC. The rationale for the design of this chemotherapy schedule was to introduce a larger number of effective drugs, including ifosfamide, into the first-line treatment, and to shorten the intervals of administration of chemotherapy by means of alternating myelosuppressive drugs with non-myelotoxic agents.
Patients and methods
Patients with a diagnosis of non-seminomatous GCTs, classified in the poor-prognosis group of the IGCCC and treated with the BOMP/EPI chemotherapy regimen between September 1985 and December 1995 were eligible for the study, and were treated at 13 different centres. All patients had one or more of the following poor-prognosis characteristics: mediastinal primary tumor, non-pulmonary visceral metastases, alpha-fetoprotein > 10,000 ng/ml, human chorionic gonadotrophin > 50,000 UI/1, or lactate dehydrogenase > 10x upper limit of normal. Patients who had undergone prior chemotherapy and those known to have the human inmunodeficiency virus were ineligible for the study.
The BOMP/EPI chemotherapy regimen is shown in Table 1 . The treatment schedule alternates cycles of BOMP with cycles of EPI, a modified VIP regimen. The initial cycle was BOMP, alternating at 14-day intervals with EPi. BOMP was administered on day 21 after the EPI. The total number of cycles administered was determined by clinical and tumor marker response, yielding a total number double that required to normalize marker levels. In the case of non-secreting tumors, patients received two additional cycles of chemotherapy after the maximal response was obtained.
Patients with very poor performance status due to advanced disease were treated initially with low-dose cisplatin (20 mg/m 2 ) and etoposide (100 mg/m 2 ) daily for three days, and the BOMP began seven to 10 days later Patients with one or more of the following features, pulmonary metastases larger than 2 cm, pulmonary metastases of any size associated with human chorionic gonadotrophin > 1,000 UI/1, or a plasmatic/CSF human chorionic gonadotrophin ratio <60, received a modified BOMP schedule that included methotrexate at a dose of 1000 mg/m 2 , rather than 300 mg/m 2 , administered in a 24-hour infusion on day 1, alternating with EPI. These patients also received methotrexate 12 mg intrathecal in weeks 2, 3 and 7 because of the high risk of subclinical spread to the central nervous system.
Patients achieving marker remission but with residual radiological masses after chemotherapy underwent surgical resection of the lesions. Response was determined by tumor marker assay, radiology and histopathology findings at post-chemotherapy surgery. Patients were classified as having achieved complete response with chemotherapy alone (tumor marker-negative, and including patients whose resected surgical mass contained only fibrosis. necrosis or mature teratoma) or as having attained complete response with chemotherapy and surgery (surgical resection of histological viable cancer). Patients whose pathology specimen showed viable residual cancer received two postoperative courses of chemotherapy (EPI or EP). Those who failed to achieve normal markers or who showed tumor progression were classified as treatment failures. Durations of progression-free survival and overall survival were calculated from the beginning of chemotherapy. Actuarial survival curves were calculated using the KaplanMeier method. Toxicity was graded by the WHO criteria.
Results
Thirty-eight patients were accrued to the study, and their characteristics are summarized in a median of seven cycles of BOMP/EPI chemotherapy (range 1-10 cycles). Six patients required an initial course of low-dose cisplatin and etoposide before the first BOMP course because of poor performance status. Sixteen patients (42%) received the modified high-dose methotrexate BOMP schedule. In 13 patients (34%) intrathecal methotrexate was added to the treatment. In three patients the BOMP was discontinued after the administration of two to four cycles of chemotherapy, because of suboptimal decline of serological markers after BOMP and appropriate decline after EPI, following their treatment with repeated cycles of EPI. Twelve patients (31.5%) received additional chemotherapy after BOMP/EPI. The causes were tumor markers' falling but without being fully normalized after several cycles of BOMP/EPI, and hematological or neurological toxicity. The additional chemotherapy given was usually a modified BOMP without cisplatin, BEP, or EP. A total of 18 patients (49%) achieved complete response with chemotherapy alone. Four had no residual radiographic abnormalities after chemotherapy, and 14 had either necrosis/fibrosis (12 patients) or mature teratoma (two patients) at postchemotherapy resection. Complete response with chemotherapy and surgery was achieved in four patients (11%) after resection of residual viable cancer. Thus, an overall favorable response was achieved in 22 patients (60%, 95% confidence interval (95% CI): 44%-75%). Four additional patients (11%) had post-chemotherapy negative tumor markers and stable residual radiological lesions that were nonresected. One patient was not evaluable for response because he died in an accident after six cycles of chemotherapy before his response had been fully evaluated. Eleven patients, including one who died during the first week of treatment and one who died of a treatmentrelated cause, were assessed as treatment failures. Two of them are currently alive and disease-free following salvage chemotherapy. Of 26 patients with favorable Figure I . Actuarial progression-free survival curve. response, 6 relapsed, all but one of them within the first year after starting treatment. Two relapses were seen in patients with residual viable cancer at postchemotherapy resection, and three in patients with non-resected residual postchemotherapy lesions. Two patients with relapse attained long-term disease-free status following salvage chemotherapy. The median follow-up time was 41 months (range 16-114 months). Actuarial progression-free survival and overall survival for all patients are shown in Figures 1  and 2 , respectively. The estimated percentage of progression-free survival at two years is 58% (95% CI: 42%-74%), and the estimated overall survival at two years is 64% (95% CI: 49%-80%). Table 3 shows severe hematologic toxic effects of the BOMP/EPI schedule for 37 evaluable patients. There were 24 episodes of granulocytopenic fever in 18 patients (49% patients). There was one death of treatmentrelated renal failure and granulocytopenic sepsis. Dose reductions for hematologic toxicity were required in seven patients, and dose delays in 20 patients. Twelve patients received prophylactic granulocyte colony-stimulating factors, after severe hematologic toxicity in previous cycles. Non-hematologic toxicity was usually mild. Grades 3 and 4 stomatitis, emesis and nephrotoxicity are shown in Table 3 . Significant neurotoxicity (grade 2 neuropathy) was seen in two patients. Other toxicities were transient and not clinically relevant. (70) 2 (5) 4 (11) 1 (3) 1(3)
1(3)

Discussion
Patients with poor-prognosis GCTs according to the IGCCC have an expected two-year progression-free survival of 50% and an overall survival of only 55% [5] . In this group of patients, new therapeutic approaches aimed to improve the cure rate are needed. Currently, the standard care for poor-risk patients remains the combination of cisplatin, bleomycin and etoposide (BEP) [8] . In recent years, several clinical trials exploring different strategies in this subset of patients have been performed. The use of alternative agents in the initial therapy has been introduced as a new treatment approach. Ifosfamide is a very active drug in salvage treatment. Recently, the introduction of ifosfamide into first-line therapy associated to etoposide and cisplatin (VIP) has been tested in a large randomized trial. VIP was compared to BEP, and the two proved similar in terms of efficacy [9] , and a second trial performed in patients with intermediate-prognosis GCTs supports these results [10] . A recently reported phase II study included in its first-line treatment five active drugs (etoposide, ifosfamide, cisplatin, vinblastine and bleomycin) against GCTs, with encouraging preliminary results [11] . Another innovative approach has been the incorporation of high-dose chemotherapy in first-line treatment of poor-prognosis GCTs. The increase of the cisplatin dose in the BEP schedule was associated with greater toxicity without an advantage in efficacy [12] . Preliminary promising results with either intensification after conventional induction chemotherapy [13] or the administration of four cycles of high-dose VIP with blood progenitor cell support [14] have been reported, and both approaches are being studied more thoroughly.
A third new strategy has been the use of alternating and sequential chemotherapy schedules. These regimens are based on the introduction of a larger number of effective drugs, alternating non-cross-resistant combinations to prevent the emergence of drug-resistant disease. An additional aim has been to shorten the intervals between treatment cycles by alternating myelosuppressive drugs with relatively non-myelotoxic combinations. POMB/ACE (cisplatin, vincristine, methotrexate, bleomycin, actinomycin D, cyclophosphamide and etoposide) has been largely employed for germ-cell cancer patients with promising results in the group of poorprognosis patients [15] . However, this regimen has never been compared to standard treatments. Additional nonrandomized trials using an accelerated sequential chemotherapy with extremely short intercycle intervals [16] and a schedule that includes cisplatin, etoposide, ifosfamide, vincristine and bleomycin [17] , have been reported in patients with poor-risk features. Two randomized trials involving alternating or sequential schedules have been reported. One trial compared four cycles of BEP to four alternating cycles of BEP plus cisplatin, vinblastine and bleomycin (PVB). There was no advantage to the alternating regimen [18] . A second large study compared the intensive sequential regimen BOP/VIP (cisplatin, bleomycin, vincristine, etoposide, ifosfamide and cisplatin) to BEP. The results showed no differences in response rates or survival times between the two regimens [19] .
The BOMP/EPI regimen is an intensive alternating regimen with shortened intervals between the BOMP and EPI cycles and the subsequent increase in dose intensity for cisplatin, the most effective of the drugs. The regimen includes in first-line treatment three essential drugs in germ-cell cancer therapy, ifosfamide, etoposide and weekly bleomycin in combination with additional active drugs with low myelotoxic effects. The number of cycles administered is adjusted to the response of markers, avoiding the policy of a fixed duration of chemotherapy. This flexible approach makes it possible to adapt the duration of the treatment to the respective patient's response.
The preliminary single-institution experience with BOMP/EPI chemotherapy in germ-cell tumors showed encouraging results in patients with different poor-prognosis features [20] . The present multicentre study demonstrates the activity and the feasibility of this schedule in the treatment of poor-prognosis germ-cell tumors. The criteria employed for the definition of poor-prognosis disease are those recently established by the IGCCC [5] and accepted worldwide. The data are derived from a multi-centre rather than a single-centre setting. The treatment was an established regimen employed in several institutions applied to non-selected patients, instead of within a clinical trial with selective inclusion criteria. These features imply that the results are unlikely to worsen substantially should the schedule be used more widely, as often occurs when single-institution trials are applied on a larger scale. The toxicity of the regimen is manageable. Hematological toxicity was the most common, and non-hematologic toxicity was generally mild. Neurotoxicity was uncommon, and we can not rule out the possibility that it may have been underestimated. The recent introduction of modern anti-emetics and colony-stimulating factors may to a greater extent overcome the toxicity observed in this series.
In conclusion, our study revealed that BOMP/EPI is active in poor-prognosis germ-cell tumors according to the IGCCC criteria. Although no firm conclusions can be drawn from this comparison, the results of the study seem to compare favorably with those expected with conventional chemotherapy [5] , and justify further studies and comparative trials to determine more exactly its value in patients with advanced germ-cell tumors. Furthermore, the incorporation in alternating regimens of new active drugs such as paclitaxel and gemcitabine may be an attractive way to optimize the potential of these strategies in the future.
*Appendix
